Source: Annual Congress 2010 - Epithelial cell biology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Pini, L. Tiberio, M. S. Ludwig, N. Venkatesan, M. Bezzi, M. Novali, L. Corda, L. Schiaffonati, C. Tantucci (Brescia, Italy; Montrèal, Canada). Intra-epithelial polymerization, accumulation and secretion of alpha₁ antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD). Eur Respir J 2010; 36: Suppl. 54, 1697

Member's Comments

No comment yet.

Related content which might interest you: Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD) Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers. Source: International Congress 2017 – New Mechanistic Findings in COPD Year: 2017 Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 501s Year: 2003 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004 Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 499s Year: 2003 The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002 Alpha 1 - antitrypsin deficiency: diagnosis and treatment Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment Year: 2021 Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005 Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD) Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008 Immune activation in α1 antitrypsin deficiency (AATD) emphysema: Beyond the protease/antiprotease hypothesis Source: Annual Congress 2012 - Mechanistic studies in airway cell biology Year: 2012 Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Characterisation of alpha-1 antitrypsin protein expression and secretion in natural killer cells from healthy volunteers and alpha-1 antitrypsin deficiency patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010